Market capitalization | $19.22m |
Enterprise Value | $-4.34m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.06 |
EV/Sales (TTM) EV/Sales | -0.21 |
P/S ratio (TTM) P/S ratio | 0.95 |
P/B ratio (TTM) P/B ratio | negative |
Dividend yield | 0.00% |
Last dividend (FY23) | $5.15 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Carisma Therapeutics forecast:
5 Analysts have issued a Carisma Therapeutics forecast:
Sep '24 |
+/-
%
|
||
Revenue | 20 20 |
91%
91%
|
|
Gross Profit | 16 16 |
82%
82%
|
|
EBITDA | -62 -62 |
14%
14%
|
EBIT (Operating Income) EBIT | -67 -67 |
10%
10%
|
Net Profit | -64 -64 |
13%
13%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.
Head office | United States |
CEO | Steven Kelly |
Employees | 107 |
Founded | 2016 |
Website | carismatx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.